Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
Early clinical data show expansion and persistence of cells and support the efficacy and safety profile of ALVR109 in transplant and non-transplant patients with COVID-19
Excerpt from the Press Release:
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced preclinical and early clinical data demonstrating that ALVR109, an investigational, allogeneic, off-the-shelf, virus-specific T cell (VST) therapy targeting SARS-CoV-2, provides antiviral activity and coverage against multiple variant strains, including Delta. The data were featured today in an oral presentation at IDWeek™ 2021.
Preclinical research from Baylor College of Medicine demonstrated the ability to rapidly characterize the cellular immune response to SARS-CoV-2 in convalescent individuals and to develop VSTs targeting immunodominant T cell target antigens within the virus. This research enabled the study of ALVR109 in four patients who were hospitalized with COVID-19 with at least two risk factors for poor outcomes. Two of these patients were not prior recipients of a stem cell transplant.
“The preclinical data presented today underscore the power of AlloVir’s virus-specific T cell therapy platform, demonstrating the speed at which we can identify target antigens, advance these to our manufacturing process and generate highly potent VSTs that are effective against a broad range of SARS-CoV-2 variant strains, including the Delta variant,” said Ann Leen, Ph.D., Chief Scientific Officer of AlloVir, and an author on the presentation. “These cells are capable of targeting not only spike, including the majority of spike-mutated T cell epitopes present in clinically important variant strains, but also four additional structural and non-structural proteins. This broad immune reactivity minimizes the potential risk of immune escape from our therapy.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?